- Home
- ICLR vs SF Comparison
ICLR vs SF Comparison
Compare ICLR & SF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ICLR | SF |
|---|---|---|
| Founded | 1990 | 1890 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 12.7B |
| IPO Year | 1998 | N/A |
Fundamental Metrics
Financial Performance| Metric | ICLR | SF |
|---|---|---|
| Price | $151.96 | $131.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 8 |
| Target Price | ★ $202.31 | $133.75 |
| AVG Volume (30 Days) | 953.9K | ★ 963.2K |
| Earning Date | 02-23-2026 | 01-28-2026 |
| Dividend Yield | N/A | ★ 1.56% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.47 | 5.87 |
| Revenue | ★ $8,102,602,000.00 | $5,529,730,000.00 |
| Revenue This Year | N/A | $13.86 |
| Revenue Next Year | $0.22 | $8.78 |
| P/E Ratio | ★ $20.15 | $22.25 |
| Revenue Growth | N/A | ★ 11.83 |
| 52 Week Low | $125.10 | $73.27 |
| 52 Week High | $211.00 | $134.74 |
Technical Indicators
Market Signals| Indicator | ICLR | SF |
|---|---|---|
| Relative Strength Index (RSI) | 22.55 | 56.42 |
| Support Level | $144.27 | $120.97 |
| Resistance Level | $191.00 | $129.68 |
| Average True Range (ATR) | 7.66 | 3.53 |
| MACD | -4.65 | 0.04 |
| Stochastic Oscillator | 2.06 | 81.92 |
Price Performance
Historical ComparisonAbout ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
About SF Stifel Financial Corporation
Stifel Financial is a diversified financial-services provider that generates revenue from wealth management, investment banking, and lending. The firm was founded in 1890 as a St. Louis-based full-service brokerage but has been transformed under CEO Ronald Kruszewski through a slew of acquisitions into a globally competitive wealth manager, investment bank, and retail and institutional brokerage. The firm generated $5.5 billion in revenue in 2025, with roughly two-thirds derived from wealth management and one-third derived from investment banking and trading.